Princeton Capital Management Inc’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Princeton Capital Management Inc’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$215K	Buy	+14,607	New	+$212K	0.11%	60

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Princeton Capital Management Inc's CNCE Position: Q3 2017 in Review

Princeton Capital Management Inc opened a new position in Concert Pharmaceuticals, Inc. (CNCE) in Q3 2017: 14,607 shares worth $215K. The stake represents 0.11% of the portfolio and ranks #60 among its holdings.

79 funds tracked by Wall St. Rank hold CNCE as of Q3 2017.

Princeton Capital Management Inc held 14,607 shares of Concert Pharmaceuticals, Inc. worth $215K as of Q3 2017.
Concert Pharmaceuticals, Inc. was a new Princeton Capital Management Inc position in Q3 2017.
Concert Pharmaceuticals, Inc. made up 0.11% of Princeton Capital Management Inc's portfolio in Q3 2017, its #60 holding.
79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2017.

Based on Princeton Capital Management Inc's 13F filing for Q3 2017, filed 3 Nov 2017.